CD19 and diffuse large B-cell lymphoma: A patient with primary refractory DLBCL involving the brain parenchyma who achieved complete remission after CAR.CD19 T-cell infusion, in the absence of cytokine release syndrome or neurotoxic effects, provides strong support that CAR T cells have the capacity to penetrate the CNS (89).